MAUDE Adverse Event Report: COOK IRELAND LTD ZILVER PTX 35 DRUG-ELUTING STENT; NIU STENT, SUPERFICIAL FEMORAL ARTERY, DRUG-ELUTING

Model Number G38483

Device Problems Biocompatibility (2886); Adverse Event Without Identified Device or Use Problem (2993)

Patient Problems Hypersensitivity/Allergic reaction (1907); Skin Inflammation/ Irritation (4545)

Event Date 09/16/2022

Event Type  malfunction  

Manufacturer Narrative

Pma # - p100022/s027.Investigation is still pending.A follow up mdr will be submitted to include the investigation conclusions.

Event Description

Per rep (b)(4) the customer stated that the patient came back in with indurated skin lesions.They wonder if the paclitaxel might be responsible for this.Did any unintended section of the device remain inside the patient¿s body? -no.If yes, please describe.Was the patient hospitalized or was there prolonged hospitalization due to this occurrence? -no.Did the patient require any additional procedures due to this occurrence? -no.If yes, please describe.Did the product cause or contribute to the need for additional procedures? -no.If yes, please specify additional procedures and provide details.Has the complainant reported any adverse effects on the patient due to this occurrence? -possibly.Has the complainant reported that the product caused or contributed to the adverse effects? -possibly.Please specify adverse effects and provide details.-indurated skin lesions.Prefix ziv6-ptx/zisv6-ptx: are images (e.G.Angiography, us etc.) of the device and/or procedure available? n/a, yes, no -no.Was the device flushed before the procedure, as per ifu? n/a, yes, no -yes.Were there any issues with flushing of the device? n/a, yes, no -no.Details of the access sheath used (name, fr size,length)? -g44154, lot 14813607.Details of the wire guide used (name, diameter, hyrdophyllic)? -.035, not cook, not hydrophilic.What approach was used to access the target site? contralateral, ipsilateral, antegrade, retrograde, other -contralateral.Please specify for other: if contralateral, was the bifurcation angle steep? n/a, yes, no -no.What was the target location for the stent? -left sfa.What artery was the stent placed in? proximal sfa, mid sfa, distal sfa, at the ostium of the profunda, p1 (proximal popliteal), other -entire sfa.Please specify for other: was the wire guide removed from the patient prior to advancing the delivery system? n/a, yes, no -no.If removed, was the wire guide wiped prior to advancement of the delivery system? n/a, yes, no -n/a.Did the stent delivery system cross the target location? n/a, yes, no -yes.Was pre-dilation performed ahead of placement of the stent? n/a, yes, no -yes.Was the patient¿s anatomy difficult or altered? previous bypass, tortuous, calcified, altered, other -no.If other, please specify: was resistance encountered when advancing the wire guide? n/a, yes, no -no.Was resistance encountered when advancing the delivery system to the target location? n/a, yes, no -no.Was resistance encountered when deploying the stent? n/a, yes, no -no.How did the physician deal with any resistance encountered? -no resistance.Was the stent fully deployed in the patient before removing the delivery system? n/a, yes, no -yes.After deployment did the stent show signs of any of the following: compression, fracture, deformation, constraint, elongation, other -no.If other, please specify: was post-dilation performed after the placement of the stent? n/a, yes, no -yes.Did any portion of the device break off? n/a, yes, no -no.If yes, please state what part: when did the device break? n/a, prep, advancement, deployment, withdrawal, after removal -n/a.Thumbwheel only ¿ was the distal end of the stability sheath inside the access sheath? n/a, yes, no -unkr.Thumbwheel only ¿ was the retraction sheet being held during deployment.N/a, yes, no -no.Did the thumbwheel spin freely or rotate without stent release or without retracting the stent retraction sheath? n/a, yes, no -it rotated freely and the stents deployed.If yes, was the stent partially deployed? n/a, yes, no -n/a.If yes, was the partially deployed stent removed with the delivery system or was it deployed in the patient? n/a, removed, deployed.If removed, did any part of the stent fracture during removal of the delivery system? n/a, yes, no -n/a.Was the delivery system kinked or twisted during advancement or deployment? n/a, yes, no -no.Please advise if and when any damage was observed on the; -n/a.Wireguide n/a, yes, no -n/a.Prior to use, during use, post procedure.Delivery system n/a, yes, no -no.Prior to use, during use, post procedur.E if yes, please specify (e.G.Kinked or twisted): what intervention (if any) was required? -none.Was the secondary intervention performed during the same procedure as the device failure or was it scheduled for another day? n/a, same procedure, another day -none were any other defects (other than the complaint issue) observed on the delivery system prior to return (e.G.Kink)? n/a, yes, no -no.Please specify if yes.

Event Description

Supplemental report is being submitted due to the completion of the investigation on 31-jan-23.

Manufacturer Narrative

Pma/510(k) # p100022/s026.Device evaluation the zisv6-35-125-6-140-ptx device of lot number c1957452 involved in this complaint was implanted in the patient and was not available for evaluation.With the information provided, a document-based investigation was conducted.3 complaints were raised to capture the presence of indurated skin lesions that occurred on the patient after the procedure.3 different stents were used in the procedure and are captured under the individual pr¿s.Document review: prior to distribution all devices are subjected to a visual inspection and functional inspection to ensure device integrity.A review of the manufacturing records did not reveal any discrepancies that could have contributed to this complaint issue.The review of relevant manufacturing records confirms the failure mode has not previously occurred for this work order.There is no evidence to suggest that the customer did not follow the instructions for use.It should be noted that the instructions for use states the following: ¿the safety and effectiveness of implanting multiple zilver ptx drug-eluting peripheral stents with a total drug coating quantity of greater than 3 mg paclitaxel (ie., an additive stent length greater than 160mm per limb) has not been established¿.¿persons with allergic reactions to nitinol, or its components, nickel and titanium, may suffer an allergic reaction to this implant.¿ ¿persons allergic to paclitaxel or structurally-related compounds may suffer an allergic reaction to this implant.¿ in addition, as per instruction for use ifu0118, potential adverse events associated with the placement of this device include the following: allergic reaction to anticoagulant and/or antithrombotic therapy or contrast medium.Allergic reaction to nitinol.Hypersensitivity reactions.Also, allergic/immunologic reaction to the drug coating is listed in the potential adverse events.Root cause review: a definitive root cause could not be determined from the available information.A possible root cause could be attributed to a possible allergic relation to nickel rather than paclitaxel coated on stent.As per medical advisor, ¿i would presume that this issue of ¿indurated skin lesions¿ was likely related to allergic reaction to nickel rather than paclitaxel coated on stent.Indurated skin lesions does occur with paclitaxel treatment; however it is via iv injection by which significant higher dosage of paclitaxel comparing to ptx stent is administrated to patient.Total dose of ptx implanted was 3.649mg which exceeded 3mg ptx, but it was not likely that the extra 0.649mg would have caused the indurated skin lesions¿.Summary: the complaint is confirmed based on customer testimony.According to the initial reporter, the patient did not require any additional procedures or was not hospitalized due to this occurrence.The physician has stated that the patient has not been seen since the initial appointment when the lesions were found.Complaints of this nature will continue to be monitored for potential emerging trends.

• Brand Name: ZILVER PTX 35 DRUG-ELUTING STENT
• Type of Device: NIU STENT, SUPERFICIAL FEMORAL ARTERY, DRUG-ELUTING
• Manufacturer (Section D): COOK IRELAND LTD; o halloran road; limerick
• Manufacturer (Section G): COOK IRELAND LTD; o halloran road; national technology park; limerick
• Manufacturer Contact: sinead o'leary ; o halloran road; national technology park; limerick
• MDR Report Key: 15596305
• MDR Text Key: 301661813
• Report Number: 3001845648-2022-00699
• Device Sequence Number: 1
• Product Code: NIU
• UDI-Device Identifier: 10827002384832
• UDI-Public: (01)10827002384832(17)240505(10)C1957452
• Combination Product (y/n): Y
• Reporter Country Code: US
• Number of Events Reported: 1
• Summary Report (Y/N): N
• Report Source: Manufacturer
• Source Type: Health Professional,User Facility,Company Representative
• Reporter Occupation: Physician
• Type of Report: Initial,Followup
• Report Date: 01/31/2023

1 Device was Involved in the Event

1 Patient was Involved in the Event

• Date FDA Received: 10/13/2022
• Is this an Adverse Event Report?: Yes
• Is this a Product Problem Report?: Yes
• Device Operator: Health Professional
• Device Expiration Date: 05/05/2024
• Device Model Number: G38483
• Device Catalogue Number: ZISV6-35-125-6-140-PTX
• Device Lot Number: C1957452
• Was Device Available for Evaluation?: No
• Is the Reporter a Health Professional?: Yes
• Was the Report Sent to FDA?: No
• Distributor Facility Aware Date: 09/16/2022
• Event Location: Hospital
• Date Manufacturer Received: 09/19/2022
• Was Device Evaluated by Manufacturer?: Device Not Returned to Manufacturer
• Date Device Manufactured: 07/04/2022
• Is the Device Single Use?: Yes
• Is This a Reprocessed and Reused Single-Use Device?: No
• Type of Device Usage: Initial
• Patient Sequence Number: 1
• Patient Outcome(s): Required Intervention
• Patient Age: 48 YR
• Patient Sex: Female